|Affiliation||Institute of Engineering|
【LIFE SCIENCE】 Yohda Unit 1
Neurodegenerative diseases such as Alzheimer’s disease are caused by the deposition of amyloid fibrils, abnormally folded protein aggregates, inside nerve cells. In recent years, it has become clear that soluble amyloid oligomers, the intermediates for amyloid fibril formation, are more toxic than fibrous aggregates, and the development of detection and removal techniques has become indispensable. Affibody, developed by Ståhl et al., Is an antibody mimic molecule that binds to various molecules using a protein as small as 58 amino acids as a scaffold. It has been studied in a variety of applications over 20 years, and more than 500 manuscripts have been published. In this study, we will develop an Affibody that binds specifically to highly toxic soluble amyloid oligomers. Simultaneously with the development of a technology for detecting soluble amyloid oligomers, the effects on amyloid formation and removal are examined by expressing the amyloid molecules in cells that express amyloid molecules. In addition, we will develop a fusion molecule of the Affibody and Hsp104, a molecular chaperone that can degrade amyloid oligomers, and analyze the effect on amyloid oligomer degradation.
|Affiliation||KTH Royal Institute of Technology (Sweden)|
|Division / Department||Division of Protein Engineering|